Remove Clinical Pharmacology Remove Packaging Remove Pharmacokinetics
article thumbnail

Optimized 505(b)(1) and 505(b)(2) Clinical Pharmacology Programs to Accelerate Drug Development

The Premier Consulting Blog

In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways. food effect, smoking, and drug-drug interactions) on drug exposure and response.

article thumbnail

Navigating the 505(b)(2) Pathway: No Two Drugs Are Alike

The Premier Consulting Blog

The 505(b)(2) submission for Bendeka included a complete chemistry, manufacturing, and controls (CMC) package, but relied on the drug master file (DMF) for Treanda. The overall development strategy for GT123 was to include a complete CMC package. daily versus four times daily dosing). Human factors.

Drugs 52
article thumbnail

Analysis Life Sciences Thank You Workshop addresses oncology dose optimization across full span of development

Agency IQ

I’m not going to say which one is better,” said JIANG LIU, scientific lead at the FDA’s Division of Pharmacometrics in the Office of Clinical Pharmacology. Then, a bit later but still in early-phase studies, developers can leverage this pharmacology information in innovative approaches that may incorporate modeling. . …

Science 40